Please check your internet connection and try again.
# IV Dexamethasone
## Overview
Dexamethasone is a potent, long-acting synthetic glucocorticoid with minimal mineralocorticoid activity. It excels due to its high anti-inflammatory and immunosuppressive potency and its negligible impact on sodium/water retention compared to other corticosteroids.
## Primary Indications
* Cerebral edema (associated with brain tumors, neurosurgery, or radiation).
* Prophylaxis/treatment of chemotherapy-induced nausea and vomiting (CINV).
* Treatment of moderate-to-severe COVID-19 (in patients requiring oxygen).
* Acute exacerbation of asthma or COPD.
* Bacterial meningitis (adjunctive therapy to prevent neurological sequelae).
* Allergic emergencies (adjunct).
## Adult Dosing
* **Cerebral Edema:** 10 mg IV load, followed by 4 mg IM/IV every 6 hours.
* **COVID-19:** 6 mg IV once daily for up to 10 days.
* **CINV:** 10–20 mg IV once prior to chemotherapy.
* **Anti-inflammatory/Immunosuppressant:** Dosage varies significantly by condition (range 0.75–9 mg daily in divided doses).
* **Bacterial Meningitis:** 10 mg IV every 6 hours for 4 days (ideally administered before or with the first dose of antibiotics).
## Pediatric Dosing
* **Cerebral Edema:** 1–2 mg/kg loading dose, then 1–1.5 mg/kg/day divided every 4–6 hours (max dose often limited by institutional protocol).
* **Croup:** 0.6 mg/kg (single dose); maximum 10 mg.
* **Bacterial Meningitis:** 0.15 mg/kg every 6 hours for 4 days.
* **Asthma:** 0.3–0.6 mg/kg (single dose); maximum 10–16 mg.
## Dose Adjustments
* **Hepatic Impairment:** Clearance may be decreased; use with caution and monitor for prolonged effects.
* **Renal Impairment:** No specific adjustment required.
## Contraindications
* Systemic fungal infections.
* Hypersensitivity to any component of the formulation.
* Avoid live or live-attenuated vaccines during high-dose immunosuppressive therapy.
## Adverse Effects
* **Metabolic:** Hyperglycemia (common, requires blood glucose monitoring).
* **Psychiatric:** Insomnia, mood swings, psychosis, or agitation.
* **Gastrointestinal:** Dyspepsia, peptic ulceration, and GI bleeding (especially if combined with NSAIDs).
* **Infection:** Increased risk due to immune suppression.
* **Other:** Hypertension, fluid retention, delayed wound healing, and electrolyte disturbances (hypokalemia).
## Key Drug Interactions
* **CYP3A4 Inducers:** (e.g., phenytoin, phenobarbital, rifampin) decrease dexamethasone efficacy.
* **CYP3A4 Inhibitors:** (e.g., ketoconazole, ritonavir) may increase dexamethasone levels.
* **NSAIDs/Aspirin:** Synergistic risk of GI ulceration and bleeding.
* **Anticoagulants:** May alter response to warfarin (monitor INR).
* **Antidiabetic Agents:** May require increased insulin/hypoglycemic dosing due to hyperglycemia.
## Monitoring
* **Glucose:** Monitor blood glucose levels, particularly in diabetic patients.
* **Clinical:** Monitor for signs of infection, GI bleeding (occult blood), and psychiatric changes.
* **Blood Pressure:** Monitor for fluid retention or hypertension.
* **Pediatric:** Monitor growth velocity if used long-term (though IV use is usually short-term).
## Clinical Pearls
* **Rapid Administration:** IV bolus can be given over 1–2 minutes; high doses for specific protocols may require slower infusion.
* **Withdrawal:** Tapering is generally not required for short courses (<5–7 days), but long-term users must be tapered to prevent adrenal insufficiency.
* **COVID-19 timing:** Clinical benefit is restricted to patients requiring supplemental oxygen or mechanical ventilation; it may be *harmful* if given early to patients not requiring respiratory support.
* **Local Protocols:** Dosing for specific oncologic or pediatric protocols (e.g., CHOP regimen) may deviate; always consult institutional clinical pathways.
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Dosing and clinical protocols can vary significantly by institution and patient status. Always verify current prescribing information, institutional guidelines, and drug compatibility (especially if co-administering with other IV medications) before administration. Consult a board-certified clinical pharmacist for patient-specific recommendations.
